CSIR-Indian Institute of Chemical Technology (CSIR-IICT) and Mylan Laboratories Limited have announced a partnership to address unmet patient needs and collaborate to identify potential therapies for COVID-19.

The collaboration will involve a series of clinical trials. Mylan is a global pharmaceutical company with vast industry experience in clinical trials and commercialization. The first of the clinical trial to be rolled out is a multiple-arm phase 3 study that will be conducted in adult patients with mild to moderate COVID-19 at risk of complications.

The application for the clinical trials has been submitted to the Drugs Controller General of India (DCGI) for regulatory approval. CSIR has appointed Dr Ram Vishwakarma, Honorary Advisor to DG-CSIR and former Director, CSIR-IIIM (Indian Institute of Integrative Medicine) as a mentor to lead this collaboration.